Last reviewed · How we verify
NCT05942001
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1 trial testing HRS-5041 in Advanced Prostate Cancer in 100 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 3 August 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- HRS-5041 — full drug profile →
Conditions studied
- Advanced Prostate Cancer — all drugs for Advanced Prostate Cancer →
Sponsor
Jiangsu HengRui Medicine Co., Ltd. — full company profile →
Who can join
Adults 18 to 80, male only, with Advanced Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Proteolysis-Targeting Chimera (PROTAC): Current Applications and Future Directions.
Fan G, Chen S, Zhang Q, Yu N, et al · · 2025 · cited 6× · PMID 41049269 · DOI 10.1002/mco2.70401 -
Recent advances in targeting protein degradation for tumor immunotherapy.
Li S, Jin Y, Wu H, Yuan H, et al · · 2025 · PMID 41345706 · DOI 10.1186/s13045-025-01765-4
Verify or expand the search:
- PubMed search for NCT05942001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HRS-5041
Trials testing the same drug.
- NCT06738745 — Study of HRS-2189 Combined HRS-5041 in Prostate Cancer · Phase 2 · not yet recruiting
Other recruiting trials for Advanced Prostate Cancer
Currently open trials in the same condition.
- NCT06769425 — HS-10502 Combination Treatment in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06335914 — Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer · NA · recruiting
- NCT06463457 — Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) · Phase 2 · active not recruiting
- NCT06866782 — European Registry of Next Generation Imaging in Advanced Prostate Cancer · recruiting
- NCT06369246 — PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Canc · Phase 1 · recruiting
Other Jiangsu HengRui Medicine Co., Ltd. trials
Trials by the same sponsor.
- NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
- NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
- NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
- NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
- NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05942001 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
- Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05942001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing